Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
HIK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,751.00p - 2,360.00p
Previous CloseN/A
Volume7.28K
Average Volume (3M)422.96K
Market Cap
£4.58B
Enterprise ValueN/A
Total Cash (Recent Filing)£213.00M
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)16.4
Beta0.80
Next Earnings
Aug 07, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 20, 2025Dividend Yield2.98%
Share Statistics
EPS (TTM)0.47
Shares Outstanding221,886,460
10 Day Avg. Volume591,095
30 Day Avg. Volume422,956
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)2.56
Price to Sales (P/S)0.00
P/FCF Ratio14.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,480.83Price Target Upside17.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Hikma Pharmaceuticals News
PremiumCompany Announcements
Hikma Pharmaceuticals Executives Involved in Share Pledge Transactions
PremiumCompany Announcements
Hikma Pharmaceuticals Projects Strong Growth and Rebrands Generics Business
PremiumCompany Announcements
Hikma Pharmaceuticals Executives Acquire Shares Under DRIPPremiumCompany Announcements
Hikma Pharmaceuticals’ Credit Rating Upgraded by S&PPremiumCompany Announcements
Hikma Pharmaceuticals Settles Xyrem® Antitrust Lawsuits in the U.S.
PremiumCompany Announcements
Hikma Pharmaceuticals Announces Managerial Share Transactions
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHikma delivered a top of range FY24 print and successfully navigated a tough comp year, delivering c.6% beat to core EBIT vs guidance at the start of 2024.
Market PositionHikma is well positioned with market tariff concerns due to a strong US manufacturing presence and limited import exposure.
Revenue GrowthStrong demand in European and MENA markets, while North America benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio.
Bears Say
Interest ChargesA 2% reduction to FY25 core EBIT and 5% reduction to adj. EPS also reflects higher interest charges.
Tariffs ImpactA market overreaction has created an opportunity for investors, as recent macro tariff news has inappropriately affected Hikma, exposing both short- and long-term opportunity.
Options Prices
Currently, No data available
---
Ownership Overview
7.71% Insiders
4.64%
Mutual Funds
― Other Institutional Investors
78.38% Public Companies and
Individual Investors
HIK FAQ
What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?
Hikma Pharmaceuticals PLC lowest share price was 1751.00p and its highest was 2360.00p in the past 12 months.
What is Hikma Pharmaceuticals PLC’s market cap?
Hikma Pharmaceuticals PLC’s market cap is £4.58B.
When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?
Hikma Pharmaceuticals PLC’s upcoming earnings report date is Aug 07, 2025 which is in 71 days.
How were Hikma Pharmaceuticals PLC’s earnings last quarter?
Hikma Pharmaceuticals PLC released its earnings results on Feb 26, 2025. The company reported 0.467p earnings per share for the quarter, beating the consensus estimate of N/A by 0.467p.
Is Hikma Pharmaceuticals PLC overvalued?
According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Undervalued.
Does Hikma Pharmaceuticals PLC pay dividends?
Hikma Pharmaceuticals PLC pays a Annually dividend of 37.805p which represents an annual dividend yield of 2.98%. See more information on Hikma Pharmaceuticals PLC dividends here
What is Hikma Pharmaceuticals PLC’s EPS estimate?
Hikma Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals PLC have?
Hikma Pharmaceuticals PLC has 221,886,460 shares outstanding.
What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?
Hikma Pharmaceuticals PLC reported an EPS of 0.467p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.185%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in GB:HIK
Hikma Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£2,480.83 (17.46% Upside)
£2,480.83 (17.46% Upside)
Blogger Sentiment
Bullish
GB:HIK Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth £140.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.19%
12-Months-Change
Fundamentals
Return on Equity
15.79%
Trailing 12-Months
Asset Growth
11.64%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
HIK Stock 12 Month Forecast
Average Price Target
2,480.83p
▲(17.46%Upside)
Technical Analysis
Allergy Therapeutics
―
Alliance Pharma
―
Animalcare
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Haleon PLC
―